Identification of a novel vaccine candidate by immunogenic screening of Vibrio parahaemolyticus outer membrane proteins
Identification of a novel vaccine candidate by immunogenic screening of Vibrio parahaemolyticus outer membrane proteins
复制标题
通过副溶血弧菌外膜蛋白的免疫原性筛选鉴定新型候选疫苗。
DOI：
10.1016/j.vaccine.2014.08.077
复制
发表时间：
2014-10-21
期刊：
影响因子：
5.5
通讯作者：
Pan, Jianyi
中科院分区：
文献类型：
--
作者：
Li, Chuchu;Ye, Zhicang;Pan, Jianyi
副溶血性弧菌是一种重要的嗜盐病原体，不仅可引起水生动物的广泛疾病，而且可因食用海产品而引起人类的严重海产品传播疾病。为了避免使用抗生素，确定保护性抗原对于开发针对该病原体的高效疫苗至关重要。外膜蛋白（OMP）已被建议作为潜在的候选疫苗，赋予保护免受感染。在这项研究中，我们确定了新的免疫原性外膜蛋白使用的免疫测定与血清抗体感染的小鼠副溶血性弧菌结合质谱分析。9种外膜蛋白被鉴定为免疫原性蛋白，其中4种在外膜蛋白谱中丰度相对较低的蛋白，LptD、VP0802、VP1243和VP0966，首次被确定为具有免疫原性。一个感兴趣的OMP，VP0802，是高度保守的主要弧菌物种之间，并提出采取β桶构象，并通过生物信息学分析OprD蛋白家族的成员。通过在小鼠模型中进行细菌激发后免疫，进一步评价VP 0802的免疫原性和保护效力。VP 0802被证实具有高度免疫原性，并提供针对副溶血性弧菌感染的强保护，RPS至少为66.7。还观察到从接种疫苗的小鼠的血液中有效清除细菌。此外，发现细菌暴露于新鲜血清后VP 0802表达上调。这些数据综合起来表明，VP 0802是用于开发预防副溶血性弧菌感染的亚单位疫苗的有希望的候选物。(C)2014爱思唯尔有限公司版权所有。
Vibrio parahaemolyticus is an important halophilous pathogen that can cause not only a broad range of disease in aquatic animals but also serious seafood-borne illness in humans as a result of the consumption of seafood. To avoid the use of antibiotics, it is critical to identify protective antigens for developing highly effective vaccines against this pathogen. Outer membrane proteins (OMPs) have been suggested as potential vaccine candidates for conferring protection against infection. In this study, we identified novel immunogenic OMPs using an immune assay with serum antibodies from mice infected by V. parahaemolyticus combined with mass spectrometry analysis. Nine OMPs were identified to be immunogenic proteins, and four of these identified proteins with relatively low abundance in OMP profiles, LptD, VP0802, VP1243 and VP0966, were determined to have immunogenicity for the first time. One OMP of interest, VP0802, is highly conserved among major Vibrio species and was proposed to adopt a beta-barrel conformation and to be a member of the OprD protein family by bioinformatic analysis. The immunogenicity and protective efficacy of VP0802 were further evaluated by bacterial challenge postimmunization in a mouse model. VP0802 was confirmed to be highly immunogenic and to offer strong protection against V. parahaemolyticus infection, with an RPS of at least 66.7. Efficient clearance of bacteria from the blood of vaccinated mice was also observed. Moreover, upregulation of VP0802 expression was found after bacteria were exposed to fresh sera. These data, taken together, suggest that VP0802 is a promising candidate for the development of a subunit vaccine to prevent V. parahaemolyticus infection. (C) 2014 Elsevier Ltd. All rights reserved.